SCHEMBL3006504

SCHEMBL3006504

Cc1cccc(C)c1-c1csc(N2CCN(S(=O)(=O)c3ccc(F)cc3)CC2)n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.72
SMN1; SMN2 Q16637 5/20 0.72
L3MBTL1 Q9Y468 1/20 0.72
MAPT P10636 3/20 0.66
USP2 O75604 1/20 0.66
RECQL P46063 1/20 0.66
HSD17B10 Q99714 1/20 0.66
LMNA P02545 6/20 0.60
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
MAPK1 P28482 3/20 0.60
TSHR P16473 2/20 0.60
HTT P42858 2/20 0.60
PKM P14618 3/20 0.52
GAA P10253 2/20 0.48
HPGD P15428 1/20 0.48
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014790 0.91 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3016735 0.90 SMN1; SMN2 (0.71) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3015535 0.89 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3003093 0.89 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3008020 0.89 SMN1; SMN2 (0.56) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3012413 0.89 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3006385 0.88 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3007717 0.87 MAPT (0.64) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3008797 0.87 HSD11B1 (0.57) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2
SCHEMBL3015549 0.87 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2L3MBTL1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.